Clinical impact of deep-vein thrombosis screening in recipients of lung transplants: A contemporary single-center study.
- 1Division of Cardiothoracic Transplantation and Circulatory Support, Baylor College of Medicine, Houston, Tex.
- 2Division of Pulmonary Medicine, Department of Medicine, Baylor College of Medicine, Houston, Tex.
- 3Section of Hematology/Oncology, Department of Medicine, Baylor College of Medicine, Houston, Tex.
Abstract
Objective
Venous thromboembolism (VTE) events are common after lung transplantation and can have a significant impact on morbidity and mortality. Our objective was to assess the impact of a deep-vein thrombosis (DVT) screening program on VTE incidence and clinical outcomes in recipients of lung transplants.Methods
We conducted a single-center retrospective study of all adults who received lung transplants (≥18 years) at our center between May 2020 and June 2024, excluding multiorgan transplants. Patients were divided into prescreening (May 2020 to June 2022) and screening (June 2022 to June 2024) groups. We evaluated VTE incidence, graft function, bleeding complications, and survival.Results
There were a total of 287 patients in the study, 130 in the prescreening group and 157 in the screening group. DVT incidence was significantly greater in the screening group compared with the prescreening group (54.1% vs 20.7%; P < .001). There was no difference in the incidence of pulmonary embolus, graft function by percent expiratory volume in 1 second predicted out to 1 year, overall survival out to 1 year, nor bleeding complications between groups.Conclusions
DVT screening in recipients of lung transplants detects clinically insignificant DVTs and may introduce potential harm from overtreatment. The use of DVT-screening programs in recipients of lung transplants should be reconsidered.
Related
- Navigating neonatal thrombosis: contemporary insights into a complex disorder in a unique population
- Understanding the Immune Response Changes to Clinical Interventions for Epstein–Barr Virus Infection Prior to Lymphoma Development in Children After Organ Transplants (UNEARTH)
- Six-Minute Walk Distance and Long-Term Outcomes in Contemporary Left Ventricular Assist Device Recipients: The ELEVATE Registry
- Retrospective evaluation of predictors and clinical impact of postoperative delirium in liver transplant recipients
- Long‐Term Proton Pump Inhibitors in Lung Transplant Recipients: Near‐Universal Use Without Clear Impact on Clinical Outcomes Over a 20‐Year Observational Study
BibTeX
@article{ramirez2026clinical,
title = {{Clinical impact of deep-vein thrombosis screening in recipients of lung transplants: A contemporary single-center study.}},
author = {Jose Ramirez and Shrikar Modukuri and Kenyon Agrons and Marcelo Salan-Gomez and Andres Leon-Pena and Jason Thomas and Colton Andrews and Allen Kuncheria and Cyrus Vahdatpour and Senthil Sukumar and Muhammad Hayat Syed and Subhasis Chatterjee and Gabriel Loor and Anh Nguyen and Nirmal Sharma and Erik E Suarez and Ramiro Fernandez},
journal = {JTCVS open},
year = {2026},
month = jul,
doi = {10.1016/j.xjon.2026.101979},
url = {https://europepmc.org/article/MED/42948589},
note = {CC BY},
}
RIS
TY - JOUR
TI - Clinical impact of deep-vein thrombosis screening in recipients of lung transplants: A contemporary single-center study.
AU - Jose Ramirez
AU - Shrikar Modukuri
AU - Kenyon Agrons
AU - Marcelo Salan-Gomez
AU - Andres Leon-Pena
AU - Jason Thomas
AU - Colton Andrews
AU - Allen Kuncheria
AU - Cyrus Vahdatpour
AU - Senthil Sukumar
AU - Muhammad Hayat Syed
AU - Subhasis Chatterjee
AU - Gabriel Loor
AU - Anh Nguyen
AU - Nirmal Sharma
AU - Erik E Suarez
AU - Ramiro Fernandez
PY - 2026
DA - 2026/07/30
JO - JTCVS open
DO - 10.1016/j.xjon.2026.101979
UR - https://europepmc.org/article/MED/42948589
AB - Objective Venous thromboembolism (VTE) events are common after lung transplantation and can have a significant impact on morbidity and mortality. Our objective was to assess the impact of a deep-vein thrombosis (DVT) screening program on VTE incidence and clinical outcomes in recipients of lung transplants.Methods We conducted a single-center retrospective study of all adults who received lung transplants (≥18 years) at our center between May 2020 and June 2024, excluding multiorgan transplants. Patients were divided into prescreening (May 2020 to June 2022) and screening (June 2022 to June 2024) groups. We evaluated VTE incidence, graft function, bleeding complications, and survival.Results There were a total of 287 patients in the study, 130 in the prescreening group and 157 in the screening group. DVT incidence was significantly greater in the screening group compared with the prescreening group (54.1% vs 20.7%; P < .001). There was no difference in the incidence of pulmonary embolus, graft function by percent expiratory volume in 1 second predicted out to 1 year, overall survival out to 1 year, nor bleeding complications between groups.Conclusions DVT screening in recipients of lung transplants detects clinically insignificant DVTs and may introduce potential harm from overtreatment. The use of DVT-screening programs in recipients of lung transplants should be reconsidered.
SN - 2666-2736
ER -